Can nuclear medicine help with a rising PSA post radical treatment?
Nuclear medicine imaging has always played an important role in the management of patients with prostate cancer, both pre and post therapy. This has primarily been through the use of conventional gamma camera imaging and bone scans for the detection of metastatic bone disease for which prostate cancer has a predilection. The role of nuclear medicine has seen recent, rapid evolution and expansion in this patient group, both because of enhanced imaging techniques for these conventional bone tracers which improve sensitivity and specificity (eg whole body single photon emission computed tomography [SPECT] and SPECT/CT) and, more recently, by the development and burgeoning availability of PET tracers.
The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.


